223 related articles for article (PubMed ID: 24779401)
1. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
[TBL] [Abstract][Full Text] [Related]
2. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
[TBL] [Abstract][Full Text] [Related]
3. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
Juengel E; Dauselt A; Makarević J; Wiesner C; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Cancer Lett; 2012 Nov; 324(1):83-90. PubMed ID: 22579787
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
[TBL] [Abstract][Full Text] [Related]
5. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Clin Exp Metastasis; 2011 Jun; 28(5):479-91. PubMed ID: 21452015
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
[TBL] [Abstract][Full Text] [Related]
7. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
8. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
9. [The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines].
Sun DF; Fang JY; Zhang YJ; Tian XQ; Zhu HY; Li EL; Gu WQ; Shen GF
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):387-91. PubMed ID: 17680526
[TBL] [Abstract][Full Text] [Related]
10. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
Wedel SA; Sparatore A; Soldato PD; Al-Batran SE; Atmaca A; Juengel E; Hudak L; Jonas D; Blaheta RA
J Cell Mol Med; 2008 Dec; 12(6A):2457-66. PubMed ID: 18266964
[TBL] [Abstract][Full Text] [Related]
11. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
Zhang P; Zhu X; Wu Y; Hu R; Li D; Du J; Jiao X; He X
Arch Biochem Biophys; 2016 Jan; 590():1-9. PubMed ID: 26558695
[TBL] [Abstract][Full Text] [Related]
13. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
14. Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2.
Chandwani S; Keilani S; Ortiz-Virumbrales M; Morant A; Bezdecny S; Ehrlich ME
PLoS One; 2013; 8(10):e76842. PubMed ID: 24204683
[TBL] [Abstract][Full Text] [Related]
15. Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro.
Makarević J; Rutz J; Juengel E; Maxeiner S; Tsaur I; Chun FK; Bereiter-Hahn J; Blaheta RA
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010254
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.
Dudakovic A; Evans JM; Li Y; Middha S; McGee-Lawrence ME; van Wijnen AJ; Westendorf JJ
J Biol Chem; 2013 Oct; 288(40):28783-91. PubMed ID: 23940046
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
[TBL] [Abstract][Full Text] [Related]
19. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
[TBL] [Abstract][Full Text] [Related]
20. Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.
Xu Q; Liu X; Zhu S; Hu X; Niu H; Zhang X; Zhu D; Nesa EU; Tian K; Yuan H
J Cell Mol Med; 2018 Mar; 22(3):1909-1922. PubMed ID: 29327812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
